NCT02909153View on ClinicalTrials.gov

Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Peritoneal Dialysis (PD)AnemiaChronic Kidney Disease
Interventions
DRUG

Triferic

Triferic is an iron salt that is approved by the FDA for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients on chronic peritoneal dialysis.

All Listed Sponsors
lead

Rockwell Medical Technologies, Inc.

INDUSTRY

NCT02909153 - Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis | Biotech Hunter | Biotech Hunter